checkAd

     809  0 Kommentare Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting

    Jazz-Sponsored Oral Presentations Include: Results from a Pivotal Phase 3 Trial for the Treatment of VOD with MOD, Sub-Analysis Data from a Phase 3 Pediatric Trial for VOD Prophylaxis, and an Exploratory Post-Hoc Analysis from an Expanded Access Treatment of VOD / SOS Study to Evaluate Timing of Treatment Initiation

    10 Jazz-Sponsored Posters Also to Be Presented

    DUBLIN, Feb. 18, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that researchers will present three Jazz-sponsored oral abstracts related to the ongoing evaluation of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with evidence of multi-organ dysfunction (MOD) following hematopoietic stem-cell transplantation (HSCT). Data will be presented at the 2016 BMT (Bone Marrow Transplantation) Tandem Meeting, the combined annual meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), taking place from February 18 to 22 in Honolulu, Hawaii.

    The three oral scientific presentations include: 1) Results from the pivotal, historically controlled Phase 3 trial of defibrotide for the treatment of hepatic VOD, also known as SOS, with MOD following HSCT; 2) results from a sub-analysis of data from an open-label, randomized, Phase 3 pediatric trial of defibrotide for the prophylaxis of VOD, including patients with specific VOD / SOS risk factors; and 3) results from an exploratory post-hoc analysis of data from an expanded access treatment of VOD / SOS study to evaluate the timing of defibrotide initiation post-VOD diagnosis and impact on Day +100 survival following HSCT.

    "The data presented at this year's BMT Tandem Meeting add to the growing body of scientific evidence regarding the efficacy and safety of defibrotide in the treatment of hepatic VOD with MOD following HSCT," said Karen Smith, M.D., Ph.D., global head of research and development and chief medical officer at Jazz Pharmaceuticals. "As we explore additional potential indications for defibrotide, the more we know, the more we might be able to do to fill unmet needs for patients."

    Seite 1 von 5


    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting Jazz-Sponsored Oral Presentations Include: Results from a Pivotal Phase 3 Trial for the Treatment of VOD with MOD, Sub-Analysis Data from a Phase 3 Pediatric Trial for VOD Prophylaxis, and an Exploratory Post-Hoc Analysis from an Expanded Access …